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spermatogenesis, and prevention of cancer. Positive selection acting on mammalian apoptosis
related genes targets protein interfaces that interact with pathogens and also elements of signaling
complexes. Selection appears primarily to be driven by the immune/defense related function of
these genes. Moreover, competitive interactions could be driving positive selection among sperm
cells, as well as the need for protection against female anti-sperm immune responses. Trade-offs
in ﬁtness are expected out of these selective pressures, which could explain the involvement of these
genes in various diseases, including cancer.
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There is a delicate balance between cell death and cell survival.
During development, cell proliferation acts in a balance with cell
death to sculpt the organs of the embryo. Tumor cells, cells in-
fected by external pathogens or cells that are irreversibly injured
have to be efﬁciently removed by the organism with minimal dam-
age. Furthermore, a normal healthy adult human produces around
1012 cells per day and cells that are in excess need to be eliminated.
This is especially true for the immune system, since after the clonal
expansion of antigen-speciﬁc lymphocytes produced after an im-
mune response is triggered, controlled cell death is needed to re-
store normal cell levels in order to avoid lymphoid neoplasia and
autoimmunity [1]. Autoimmunity is also tightly constrained by
the elimination of auto-reactive immune cells [2].
The elimination of cells through a controlled set of biochemical
processes called programmed cell death (PCD) usually occurs via
apoptosis and is morphologically characterized by cell shrinkage
and subsequent engulfment by macrophages, with no damage to
the adjacent tissues. An uncontrolled PCD results in disease, such
as neurodegenerative disorders, ischemic injury, cancer, autoim-
mune disorders and chronic infections.chemical Societies. Published by E
ology, University of
mark.
da Fonseca).There are various pathways involved in cell death (Fig. 1). Mol-
ecules such as interleukins (IL) and interferons (IFNs, involved in
inﬂammatory responses) occur early in the signaling cascades
[3,4]. The intrinsic (or mitochondrial) pathway is the most ancient
one [5] and involves the release of molecules trapped in the mito-
chondrial intermembrane space leading to apoptosis through di-
rect DNA fragmentation [6]. It can also activate the caspase
cascade, which is central in many apoptotic pathways [6]. The
extrinsic pathway involves the activation of death receptors on in-
fected/damaged cells by cytokines produced by immune system
cells [6]. This leads to the direct activation of the caspase cascade
and also of the intrinsic pathway. Immune system cells also pro-
duce granzymes, powerful proteases that efﬁciently kill damaged
cells after being injected into their cytoplasm, either by direct
DNA fragmentation or activation the caspase cascade [7,8]. Fur-
thermore, two transcription factors balance cell life and death:
p53 responds to various types of cellular stress and DNA damage
by initiating cell-cycle arrest or triggering apoptosis [9]; and nucle-
ar factor kB (NF-kB) complexes are crucial for protection against
apoptosis, not only in normal cells, but also in cancer cells and cells
infected by intracellular pathogens [10,11].
Despite the fundamental role of apoptosis and the fact that the
equilibrium between cell life and death is fragile, apoptosis related
genes in humans tend to show strong evidence for positive Dar-
winian selection [12]. This means that mutations that change the
amino acid sequence accumulate in these genes at a higher rate
than it is predicted for a gene where substitutions among specieslsevier B.V. All rights reserved.
Fig. 1. The major pathways of cytotoxic T lymphocyte induced apoptosis and the mitochondrial intrinsic pathway. Representative steps of the NF-kB pathway are also
depicted. Molecules targeted by pathogens are indicated in red [45,64–69].
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parative data, positive selection acting on a coding sequence is
generally detected by calculating the ratio of non-synonymous
mutations (those that change the amino acid) per non-synony-
mous site to the number of synonymous mutations (that keep
the amino acid) per synonymous site (dN/dS =x). If mutations are
allowed to accumulate randomly (if there is no selection), x is ex-
pected to be equal to 1. If the function of the gene is tightly main-
tained, and most mutations are neutral or deleterious, x is
expected to be below 1, indicative of negative selection (most
genes, particularly housekeeping genes, fall into this category
[13]). Positive selection (x > 1) occurs when there is some advan-
tage in changing the gene function, such as in the case of proteins
that recognize pathogenic molecules, and is characterized by rapid
evolution. Importantly, positive selection is not indicative of func-
tional importance in itself; positively selected genes may or may
not be more functionally important than other genes. Rather, the
presence of positive selection shows that the genes involved have
provided evolutionarily adaptive responses to internal or external
environmental changes, or otherwise have been involved in a
dynamics that would selectively have favored changes of the
genes. For more examples and an extensive description of positive
selection at the molecular level see [14].
Given that apoptosis is critical to normal development and
function, why are apoptosis related genes not highly functionally
constrained, but seem to change faster than many other genes in
mammals? A number of different hypotheses can be erected:
(1) Positive selection may simply act to optimize protein func-
tion in a ﬁxed environment. Many apoptosis related genes
may be newly evolved genes that are still being optimized
through natural selection, and are, therefore, still evolving
rapidly.(2) The selection acting on apoptosis related genes has to do
with the role of apoptosis in immunity and defense. Many
immune and defense related genes are evolving very rapidly
to adapt to the constantly changing pathogenic environment
[e.g. [15–19]] .
(3) Positive selection could be driven by: (i) competitive interac-
tions among sperm cells as suggested by Nielsen et al. [12],
since selﬁsh mutations contributing to the inhibition of
apoptosis are favored by segregation distortion (meiotic
products carrying such mutations may have a larger chance
of developing into mature sperm cells); (ii) the need for pro-
tection against anti-sperm immune responses in the female
reproductive tract.
However, given the pleiotropic nature of many of these genes,
ﬁnding speciﬁc causes for selection on apoptosis related genes is
difﬁcult. The same apoptosis machinery is often involved in de-
fense against pathogens, prevention of cancer, spermatogenesis,
etc (e.g. see Tables 1 and 2 provided as Supplementary data). In
addition, the pleiotropic effects of mutations in the genes are likely
to cause trade-offs in ﬁtness relating to different functions of the
gene. Selection relating to, for example, viral defense may also af-
fect other functions such as cancer prevention. However, muta-
tions increasing functionality with respect to viral defense may
not necessarily be optimal in terms of cancer prevention. Such
trade-offs in ﬁtness due to the multi-functionality of the apoptosis
machinery may in itself help drive repeated positive selection, and
help explain why these genes are not highly conserved despite
their important functions.
A recent study has allowed further elucidation of the selective
forces acting on apoptosis related genes. Kosiol et al. [20] per-
formed a genome-wide scan in search for positively selected (PS)
genes using six high-coverage genome assemblies for eutherian
Table 1
Apoptosis related genes under positive selection as inferred by likelihood ratio tests implemented in PAML (P-value < 0.001).
Gene symbol P-value Function Immune efﬁciency Immune regulation and homeostasis Cancer
EMP2 3.9E09 Required for MHC1 expression X
CASP10 8.3E08 Proapoptotic (TNFR pathway) X
CARD8 1.7E07 Proapoptotic (NF-kappaB pathway inhibitor) X
CCNB3 2.2E06 Spermatogenesis (cell-cycle arrest)
IFNA8 3.0E06 Proapoptotic; antivirus X X
CTSG 3.1E06 Proapoptotic; protease; inﬂammation X
CARD6 4.3E06 Antiapoptotic X
HTRA4 5.6E06 Proapoptotic; stress conditions
GZMB 8.6E06 Proapoptotic; antipathogen X
EMP1 9.4E06 Expressed at high levels in proliferating cells X
TNFRSF11A 1.4E05 Proliferation (bone development) X X X
CD3E 2.1E05 T-Cell maturation X
CD3G 2.2E05 Early thymic development X
CASP8 2.3E05 Proapoptotic (TNFR pathway) X
GZMH 2.7E05 Proapoptotic; antipathogen X
TMEM16J 4.5E05 Proapoptotic; induced by p53
HSPA1B 1.2E04 Antiapoptotic under stress conditions X
SET 3.3E04 Antiapoptotic; GrA substrate X X
IL3RB 3.4E04 Proliferation (hematopoietic cells); immunity X X X
ARHGEF1 3.6E04 Proapoptotic in thymocytes X X
COL4A3 3.6E04 Proapoptotic in endothelial cells X
NOX5 4.1E04 Antiapoptotic X X
IFNA17 4.6E04 Proapoptotic; antivirus X X
APOL6 5.5E04 Proapototic
CD5 6.1E04 Modulates B- and T-cell receptor signaling X
SPN 6.3E04 Proliferation and apoptosis in T-cells X X
TNFAIP8L3 6.5E04 Induced by tumour necrosis factor alpha
PTPRC 8.3E04 Signal transduction in T- and B-cells X
CDKN2A 9.7E04 Apoptotic (indirectly activates P53); aging X
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ﬁed 400 genes with strong evidence of positive selection
(FDR < 0.05) and a larger set of 1596 with moderate evidence of po-
sitive selection (nominal P < 0.05). Ninty two of the latter were
associated with apoptosis (Tables 1 and 2).
In this study we will provide a detailed discussion of the apop-
tosis related genes undergoing positive selection on the mamma-
lian phylogeny based on the Kosiol et al. study and also on
additional analyses of selected genes. We ﬁrst present a summary
of the apoptosis related genes under positive selection and we then
focus on particular sets of genes grouped according to signaling
pathways and/or biological and molecular function, in order to elu-
cidate the factors causing positive selection in these genes. We will
argue that genes involved in early signaling and that are very di-
rectly involved in early responses to pathogens are more likely to
be under positive selection than other apoptosis related genes.
We also argue that the timing of expression of various apoptosis
related genes during spermatogenesis suggests a possible role for
the third hypotheses outlined above. Finally, we make an overview
of the relationship between apoptosis related PS genes and dis-
ease., and suggest that the rapid evolution of these genes may help
explain the high prevalence of certain diseases. Our objective is not
to review functional aspects of apoptosis, except when needed to
understand the evolutionary hypotheses. We refer instead the
reader to reviews in [1,6,7,21].
2. Methods
In this work we have used the 16529 genes selected as de-
scribed in [20] and the set of positively selected genes that had
nominal P values < 0.05 (total of 1596 genes). Statistical detection
of positive selection can be sensitive to errors in sequencing, anno-
tation and alignment [22]. Therefore, the set of orthologous genes
proposed by Kosiol et al. [20] were subject to a series of rigorous
ﬁlters for synteny, alignment quality, conservation of intron and
exon structure and sequence quality [23]. Genes resulting from re-cent duplication events were excluded from the analyses of posi-
tive selection (only high-conﬁdence 1:1 orthologs were
considered). Likelihood ratio tests (LRTs) were used to identify
genes under positive selection (x > 1) by comparing two probabi-
listic models of variablex ratios among sites, the simpler of which
does not allow sites withx > 1 and a more general which does (see
[20] for more information). In the following sections, P values for
the test for positive selection will be presented within a parenthe-
sis. GO [24] and PANTHER [25] ontologies were used to identify
biologically meaningful categories. Apoptosis related genes have
been deﬁned as those that are annotated as such under either GO
or PANTHER categories (total of 789). The Atlas of Genetics and
Cytogenetics in Oncology and Haematology [26] was used to iden-
tify cancer-related genes (30% of the total number of genes in our
sample). Fisher’s exact test (FT) was used to identify an excess of PS
genes in individual categories within the apoptosis- and cancer-re-
lated genes. The results were corrected for multiple testing using a
FDR of 0.05. For a limited set of genes with available X-ray struc-
tures, we used the Bayesian empirical Bayes (BEB) method under
the M8 model implemented in PAML [27] to determine the amino
acid sites under positive (Fig. 3). For these analyses we used the
alignments provided in Supplementary data that correspond to
those in Ref. [20] plus extra available mammalian sequences for
each gene. Three-dimensional protein structure models were built
using Modeller [28]. The model for the extracellular domain of Fas
complexed with FasL was built using the structures for TRAIL-R2
complexed with TRAIL and that of TNF-R1 complexed with TNFB
as templates (PDB ids: 1DU3 and 1TNR, respectively). The interac-
tion between the DD of Fas and the DD of FADD is represented as in
the DISC structure (PDB id: 3EZQ).
3. Apoptosis related genes under selection
A list of some individual apoptosis related genes showing evi-
dence of positive selection can be found in Table 1. There is a clear
overlap among PS genes related to apoptosis, immune response,
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(Fig. 2). We ﬁnd that 48% of the PS apoptosis genes are involved in
cancer, 12% in neuronal function/disorders, and 11% in cardiovas-
cular diseases (Fig. 2). To some degree, these associations mirror
those found in general among these categories, also in genes with-
out positive selection.
Most of the apoptosis related genes under positive selection are
related to the immune system (P = 4E02), particularly in response
to viruses (P = 6.8E03) (see Table 3 provided as Supplementary
data). In fact, viruses have developed numerous mechanisms for
interfering with early antiviral signaling [29], which may explain
the large number of genes under positive selection that participate
in it.
4. Pathways under selection
4.1. Early rather than late (inﬂammation and cell signaling)
PS apoptosis related genes are located mainly upstream on the
cascade events that lead to apoptosis/survival, at the level of cyto-
kine activity (P = 1.2E02) and transmembrane receptor activity
(P = 3.0E02). Clearly, selection acting to reduce or limit the effect
of apoptosis would be expected to affect the very early stages of
the apoptotic signaling and not the later stages. Positive selection
relating to adaptation to apoptosis manipulation by pathogens
leads to similar predictions: interference by pathogens on the host
apoptosis machinery is much more efﬁcient if it occurs before the
cell already has begun the initial, typically irreversible, steps of the
apoptosis process. Several signaling molecules and their receptors
have been found to be under positive selection (Fig. 1). These are
cytokines, such as interleukins (ILs) and interferons, which are
molecules involved in intercellular signaling. These molecules are
among the favorite targets of viral manipulation via the production
of viral decoy receptors and proteins that sequester these cytokines
[4,29].
4.2. The extrinsic pathway
We ﬁnd that the genes in the extrinsic and granzyme pathways
(Fig. 1) are signiﬁcantly enriched with positive selection compared
to those of the intrinsic pathway (P = 3.1E03; Table 4 in Supple-
mentary data). The intrinsic pathway is primarily involved in
inducing apoptosis relating to internal stimuli such as cell damage.
Signals resulting from the detection of foreign molecules, such as
those from pathogens, are relayed by the extrinsic pathway. The
excess of positive selection in the extrinsic rather than intrinsic
pathway demonstrates that positive selection is not being driven
by the role of apoptosis in processes relating to cell damage or
other equilibrium processes (intrinsic pathway, Fig. 1), but is pri-Fig. 2. Venn diagram representing the biological processes associated with the 92
positively selected genes involved in apoptosis found in our sample. The different
elements are proportional to the number of genes for each category, indicated in
parenthesis.marily related to interactions with pathogens or other factors
external to the cell. While the extrinsic pathway may be more re-
cently evolved than the intrinsic pathway, it predates the chordate
lineage [5,30]. Several genes are present outside the mammalian
group. For example, the zebraﬁsh harbors several elements of the
death-receptor pathway [30], including Fas (Fig. 3A). It is therefore,
unlikely that the excess of evidence for positive selection is caused
by a recent origin of the genes in this pathway. This conclusion is
also supported by the fact that positively selected sites present a
number of amino acids with different chemical properties, indica-
tive of repeated mutations (in Fas, for site 239, we ﬁnd e.g. Val, Lys,
Asp and Gln; for site 315, we ﬁnd e.g. Leu, Trp, Gln and Met).
Others have previously observed an overall accelerated rate of
protein sequence evolution in genes involved in caspase-depen-
dent pathways [31]. The PS genes in the extrinsic and granzyme
pathways are either directly (direct binding) or indirectly (homo-
logue decoy pathogen-expressed molecules) affected by pathogens
(see Fig. 1). The extrinsic pathway is important in immune and de-
fense related apoptosis in response to viral infections, regulation of
homeostasis of the immune system and is also thought to play an
important role in apoptosis during spermatogenesis [32–35].
Apoptosis is triggered by the tumor necrosis factor ligands (e.g.
Fas ligand (FasL)), which binds to tumor necrosis factor receptors
(e.g. Fas, P = 1.6E03, see Fig. 3A) [21].
The Fas/FasL system is essential in the control of the immune
response homeostasis as shown by the uncontrolled accumulation
of lymphocytes when it is affected by loss-of-function mutations
[36]. FasL also acts as an immunosuppressant in immune privi-
leged sites such as testis, eye, placenta and brain, and in tumors
[37,38]. Fas receptors form homotrimers [39] that bind FasL mole-
cules through their extracellular domains [40]. The intracellular
death domain (DD) binds to Fas associated protein with death
domain (FADD) which then binds the inactive pro-CASP8
(P = 2.3E05) and pro-CASP10 (P = 8.3E08), a step that precedes
maturation of the caspases (removal of the pro-domain). c-FLIP
can bind FADD and CASP8 inhibiting this step [41]. Mature
CASP8/10 cleave CASP3/7, triggering cell death.
The positively selected sites in Fas fall into several regions cru-
cial for signaling (see Fig. 3A). On the extracellular domain, the
sites sit in the region that affects the pre-association of Fas mole-
cules and ligand binding [39]. One positively selected site (239 in
the human sequence) found on the intracellular DD sits on the
interface with FADD, and changes from a small apolar valine in hu-
mans to a long positively charged lysine in the rat, which will very
likely have a profound effect on the binding between the two mol-
ecules. Another PS site (315 in the human sequence) presents
either a leucine residue (human) or tryptophan residue (rat). Curi-
ously the side-chains of that site in two Fas molecules interact with
each other, suggesting a major impact on the association between
the different Fas molecules, essential to receptor activation [42].
What is driving positive selection in Fas? One possibility is the
interaction with inhibitory viral molecules, since viral counterparts
of c-FLIPs (v-FLIPs) and other viral molecules have been shown to
interact with Fas, CASP8 and CASP10, inhibiting apoptosis [43–45].
Positive selection acting on Fas may result from the need to avoid
inhibition by pathogenic molecules. Another possible contribution
to the selective pressures on the extrinsic pathway elements is re-
lated to segregation distortion occurring in the male reproductive
system, which will be discussed in the next section.5. Spermatogenesis
Humans produce approx. 2  108 sperm cells per day, and up to
3/4 of the potential spermatozoa die by apoptosis in mammals
[34]. This is thought to occur because of the limited capacity of
cC
B
A
Fig. 3. Mapping of positively selected sites (P > 0.9) on protein structures of apoptosis related genes. (A) Fas trimer associated with FADD. Positively selected sites are shown
in red. Side chains for residues 239 and 315 in humans (red transparent surface) and rat (sticks) are depicted for comparison. (B) Superposition of the crystallographic
structures of four homologous serine proteinases implicated in apoptosis (PDB ids: CTSG (cathepsin G): 1T32; CMA1 (chymase): 1T31; GZMA (granzyme A): 1ORF; GZMB
(granzyme B): 1IAU). Residues under positive selection are show as spheres with colors according to the enzyme they belong to. The inhibitors bound to CTSG and CMA1 are
show as white spheres, depicting the active site. (C) Positively selected residues mapped on the CD3c heterodimer structure (PDB id: 1SY6). Residues in green indicate the
interface between the two monomers, a region shown to be important for signal transduction [70]. Residues in orange are located around the suggested binding patch for the
TCRab receptor [71]. Antibodies to CD3 bind the area depicted in yellow [71,72]. Residues in blue cover a big extension of CD3c exposed surface, but have not been assigned
any function yet.
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abnormalities [46]. Apoptosis in adult male testis affects mainly
spermatogonia, but also spermatocytes and spermatids, and a cor-
relation has been found between the occurrence of apoptosis and
the DNA replication phase in these cells [47,48].Fas expression has been shown to be correlated with human
germ cell degeneration in meiotic and post-meiotic arrest of sper-
matogenesis (Fig. 4) [35]. Furthermore, c-FLIP, an inhibitor of Fas-
induced apoptosis (Fig. 1) has been shown to be expressed in sper-
matogonia, spermatocytes and spermatids [49], with a cell-speciﬁc
Fig. 4. Apoptosis related genes expressed in germ cells during the different stages
of spermatogenesis.
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cates the need for protection against death-receptor pathway-
mediated apoptosis during spermatogenesis.
The Fas/FasL system is suggested to be involved in at least two
ways in the male reproductive system: (i) it eliminates defective
and excessive cells during spermatogenesis; (ii) FasL protects sper-
matozoa against the immune response (e.g. lymphocytes display-
ing Fas) that takes place after insemination in the female genital
tract [32,33]. Furthermore, the expression of FasL in sperm cells
might also be involved in competitive interaction with other sperm
cells as suggested in Nielsen et al. (2005). Interestingly, genes in-
volved in Fas mediated apoptosis signaling within the cell tend
not to be expressed after meiosis II. In contrast, FasL, capable of
transmitting an apoptosis signal to other cells, is being expressed
after meiosis II (Fig. 4). This is exactly as predicted if apoptosis is
playing a role in competitive interactions among sperm cells,
either from the same or from different individuals. However, the
continued expression of FasL may also protect sperm cells against
the female immune system. In either case, a competitive evolution-
ary dynamics will arise akin the host–pathogen interactions driv-
ing most of the positive selection in the human genome. It is
likely that the role of apoptosis in spermatogenesis is an important
factor driving positive selection relating to Fas mediated apoptosis.
6. Pattern recognition vs modulation of signal
Positive selection in immune defense-related genes is quite per-
vasive, in particular for genes speciﬁcally involved in the recogni-
tion of pathogen molecular patterns [15–19]. In the previous
sections we have described how the direct contact with pathogens
could be driving positive selection in a variety of apoptosis related
genes. Another interesting example is that of a set of structurally
related serine proteases responsible for cleaving protein sub-
strates. Granzymes (see the perforin/granzyme pathway on
Fig. 1), chymase, and cathepsin G are powerful enzymes all in-
volved in immune defense. Fig. 3B displays four superimposed
structures of these serine proteases, and we can see that, overall,positive selection (sites shown as spheres) is targeting the loops
that surround the active site area (occupied by inhibitor molecules
in white). These loops have been shown to be responsible for sub-
strate speciﬁcity and the control of activation of the enzymes. This
leads us to suggest that the interaction with pathogens is driving
positive selection in these enzymes, changing or broadening their
speciﬁcity for foreign molecules, thereby calibrating their direct
antimicrobial action and their role in the modulation of the im-
mune response.
We have also found a number of apoptosis related positively se-
lected genes that do not seem to be direct targets of pathogens, but
are also involved in providing a healthy immune response. These
genes are involved in either or both immune system development
and efﬁcacy, such as CD5 (P = 6.1E04) that regulates both the
selection process in thymocytes and the survival of activated B-
and T-cells [51], or PTPRC (aka LCA or CD45, P = 8.3E04) that is in-
volved in both signal transduction through T- and B-cell receptors
[52] and in early thymocyte development, taking part in the selec-
tion of CD4+CD8+ thymocytes, and B cell maturation [53]. Also the
CD3 antigen, which is the signal transducing component of the ab
T-cell receptor (TCR) complex in mature lymphocytes, is under po-
sitive selection (Fig. 3C). The abTCR heterodimer is responsible for
ligand recognition (MHC/peptide complexes) and subunits CD3
(P = 2.11E05) and CD3c (P = 2.19E05), which are components
of the signal transduction system, have an essential roles in T-cell
development [54,55]. The sites affected by positive selection seem
to be involved in the efﬁciency in signal transduction (see Fig. 3C).7. Cancer and autoimmune diseases
Cancer-related genes experience more positive selection than
other genes (Table 3; P = 1.9E03). This is largely explained by a
strong association between PS genes and immune response (Table
3; P = 4.1E18) and a general association between immune re-
sponse genes and cancer-related genes (Table 3; P = 2.9E26).
The association between immune response and cancer, opens the
possibility that much positive selection is responding to changes
in trade-offs in ﬁtness between the effects relating to the func-
tional role of the genes in immune/defense, and the role of the
genes in cancer. This will be especially important if the effects of
changes in the gene on ﬁtness, is opposite with respect to the
two (or more) functions of the protein. A number of apoptosis re-
lated PS genes are involved in multiple processes associated with
both tumor development and wound healing and inﬂammation,
such as tissue invasion and metastasis (EMP1, P = 9.4E06) and
vascularization and angiogenesis (COL4A3, P = 3.6E4) [56,57].
The same events involved in acute inﬂammation and healing also
occur during carcinogenesis and chronic unresolved inﬂammation,
although in a chaotic order [58]. We then might expect that
changes that result in a better recovery from damage caused by
infection could have a negative impact on ﬁtness (e.g. a more efﬁ-
cient formation of blood vessels that rapidly restore oxygenation
and provide nutrients to damaged tissues, may also contribute to
better support of a developing tumor). Small changes in the path-
ogenic environment, may change the optimum of the trade-off of
these pleiotropic effects of the gene, and induce it to evolve to-
wards the new optimum (see Fig. 5).
A similar dynamic might arise due to the dual effect on changes
in apoptosis related genes for defense against pathogens, and in
autoimmune diseases. Indeed, genes involved in the immune re-
sponse may at times have a negative impact on ﬁtness. For exam-
ple, genes involved in signaling in inﬂammatory processes play a
major role in diseases such as rheumatoid arthritis [59]. Proteins
with enzymatic activity, such as CTSG and CMA1, are also involved
in autoimmune disease (e.g. asthma [60,61]). Both CMA1 and CTSG
Fig. 5. Changes in the environment can lead to reduced ﬁtness by altering the
balance between an adequate immune response and disease.
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the surfaces that interface with the external environment in the
body, the main media for pathogen inﬁltration. Mast cells respond
to danger signs of innate and acquired immunity by releasing sev-
eral inﬂammatory mediators [62]. The immune hyper-responsive-
ness associated with CTSG and CMA1 might be the result of a
dynamic that balances the strength of the immune response in a
particular pathogenic environment, with the possible negative ef-
fects of hyper-responsiveness. Again, changes in the pathogenic
environment may offset this balance and induce positive selection.
For example, it is possible that, in recent human evolutionary his-
tory, as the density of the populations have increased, pathogens
were more easily transmitted, leading to selection that might favor
a different optimum in the trade-off between increased response to
pathogens and decreased risk of autoimmunity disease. A trade-off
between the collateral damage caused by the immunoresponse
during infection and the efﬁcacy of the response to pathogens
may lead to a similar dynamic.
8. Conclusions
(1) Death by apoptosis involves a very complex signaling sys-
tem for eliminating excessive, defective or infected cells. It
is one of the common targets of manipulation by pathogens,
attempting to induce the death of immune system cells, or to
delay the death of the cell they have colonized. As predicted
under the immune/defense selection hypothesis, most posi-
tive selection appears to involve early signaling rather than
late signaling, and does not appear to be related to intrinsic
pathways involved in the elimination of defective cells.
Instead, positive selection in a number of apoptosis related
genes is likely driven by an evolutionary arms race between
host and pathogens.
(2) The expression pattern of apoptosis related genes under
positive selection also lends support to hypotheses involving
competition among sperm cells or interactions between
sperm cells and cells from the female immune/defense
system.
(3) There are two main biochemical features that are changed
by positive selection: (i) protein–protein interfaces interact-
ing with molecules produced by pathogens (e.g. viral mole-
cules such as v-FLIP); (ii) regions involved in the modulation
of signaling (e.g. CD3).
(4) Positive selection and antagonistic pleiotropic effects may
help explain the segregation of apparently deleterious muta-
tions relating to autoimmune disease, cancer, and other
apoptosis related functions. Many of the PS apoptosis relatedgenes have multiple biological roles and so mutations in
apoptosis related genes may, therefore, have antagonistic
pleiotropic effects. This might in part explain patterns of
repeated positive selection in apoptosis related genes, as
compensatory mutations may follow initial beneﬁcial muta-
tions. For example, increased risk of cancer may be a nega-
tive outcome associated with positive selection related to
the immune/defense, or other, functions of apoptosis genes.
Mutations limiting apoptosis for certain germ cells, may pro-
vide a ﬁtness advantage for the germ cell, but may lead to
negative ﬁtness effects for the mature organism in terms
of increased risk of cancer or reduced response to pathogens.
Likewise, mutations increasing the apoptosis response may
lead to an improved response to pathogens, but an increased
risk of autoimmune disease, etc. In changing environments,
we would expect a changing balance in the trade-off
between different effects of apoptosis to drive evolutionary
changes at the molecular level. For example, the increased
prevalence of autoimmune disorders has been linked to
changes in human exposure to pathogens [63], indicating
that adaptation to past environmental conditions leads to
reduced ﬁtness in the absence of those conditions.
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